Trauma-focused psychotherapy (tf-PT) is the first-line treatment for posttraumatic stress disorder (PTSD). Tf-PT focuses on processing and modulating trauma memories. Not all patients benefit, however, and there is room for improvement of efficacy. Pharmacologically augmenting trauma memory modulation in the context of tf-PT may help optimise treatment outcome. To systematically review effects of pharmacologically augmented memory modulation in the context of tf-PT for PTSD (PROSPERO preregistration ID: CRD42021230623). We conducted a systematic review of randomised controlled trials of psychotherapy treatment for PTSD. We included placebo-controlled studies that augmented at least one treatment session pharmacologically targeting memory extinction or reconsolidation. We calculated post-treatment between group (pharmacological augmentation vs placebo control) effect sizes of PTSD symptom severity. We included 13 RCTs. There was large heterogeneity in augmentation procedure and methodological quality. Four studies showed significantly greater PTSD symptom reduction in the pharmacological augmentation group (propranolol, hydrocortisone, dexamethasone, D-cycloserine) compared to placebo. Seven studies showed no significant effect of pharmacological augmentation compared to placebo (D-cycloserine, rapamycin, mifepristone, propranolol, mifepristone combined with D-cycloserine, methylene blue). Two studies showed significantly smaller PTSD symptom reduction in the pharmacological augmentation group (D-cycloserine, dexamethasone) compared to placebo. Results of pharmacological augmentation were mixed overall and heterogenous for the pharmacological agents tested in more than one study. Additional studies and replications are needed to identify which pharmacological agents work, in which combination and to identify patient groups that benefit most to tailor PTSD treatment.
A core clinical feature of posttraumatic stress disorder (PTSD) is recurrent reexperiencing of the traumatic event in the form of intrusive memories. Doxycycline is a matrix metalloproteinase 9 (MMP-9) inhibitor. MMP-9 is required for late-phase, NMDA receptor-dependent long-term potentiation in the hippocampus and the basal and central amygdala nuclei, which are important to various forms of learning and memory. Here we examined the effect of doxycycline on the development of intrusive memories in a pre-registered randomized, double-blind, placebo-controlled trial ( https://osf.io/72ys9 ). Healthy females (N = 80) received 200 mg doxycycline or placebo 4.5 h before exposure to film footage depicting strong interpersonal violence. Participants then completed an intrusion diary for one week. Most participants, 92%, experienced intrusive memories following the trauma film. There was no evidence that doxycycline and placebo groups differed in frequency, distress, and vividness of daily intrusive memories models. The doxycycline group showed enhanced arousal, indexed by skin conductance when exposed to reminder cues, and better performance in a memory task about film content compared to placebo one-week post-film. Based on our findings, the MMP9-inhibitor doxycycline did not impair the development of intrusive memories and was associated with increased arousal and improved retrieval of experimental trauma memory one week later.